Physician profile
Deena M Rodney
NPI 1932408028
$322,541.64
in general payments reported to CMS, 2019-2025
72 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40K · 2022: $71K · 2023: $50K · 2024: $64K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Travel and Lodging: $41K · Consulting Fee: $26K · Food and Beverage: $25K · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,555.50 |
| Travel and Lodging | $40,610.45 |
| Consulting Fee | $26,335.78 |
| Food and Beverage | $25,082.25 |
| Education | $126.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $176,780.55 | 2021-2025 | Ultomiris, Soliris |
| Ucb, INC. | $34,495.76 | 2021-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Janssen Biotech, INC. | $28,007.08 | 2025 | |
| Allergan, INC. | $21,235.54 | 2021-2022 | |
| Abbvie INC. | $20,100.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10,959.67 | 2023-2025 | Hyqvia, Gammagard |
| Amgen INC. | $10,819.47 | 2021-2025 | Uplizna |
| Argenx US, INC. | $4,235.62 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $2,145.05 | 2021-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $1,498.37 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $1,027.74 | 2021-2025 | |
| Genzyme Corporation | $808.29 | 2021-2025 | |
| Lilly USA, LLC | $664.12 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $623.47 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $592.52 | 2021-2025 | Mavenclad |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deena Rodney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.